PRA Group at 0.66x Book: A Real Recovery With a Bookkeeping Beat

Management carried PRA Group's pitch to investors at the 2026 Midwest IDEAS Conference on Wednesday, and the pitch almost writes itself: a debt collector that lost more than $10 a share in a single 2025 quarter, then cut costs, rebuilt its collection forecasts, and started buying back stock below its own book value. The market has already noticed. The shares have climbed from a 52-week low of $10.25 to about $19.45 — up roughly 90% from the bottom — and the stock still trades at 0.66x book value, about a third of the roughly 2x book multiple that its closest pure-play rival, Encore Capital, carries. That gap is the whole question: a recovery the market hasn't credited, or a discount the market has earned.

Start with the mechanics, because the model cuts both ways. PRA buys charged-off consumer debt — stale credit-card and installment balances — for cents on the dollar, then works the accounts. Its assets are mostly those portfolios, financed heavily with borrowed money: net debt of about $3.5 billion against a market cap of $732 million. Leverage is the business model, and when collections miss the forecast, the loss lands on a thin slice of equity.

That is precisely what 2025 was. In Q3, PRA recorded a $413 million non-cash goodwill impairment — a write-down of what past acquisitions had cost relative to what they are now expected to return — the quarter printed a -$10.43 EPS, and the year ended with a $305 million net loss. This is why trailing valuation multiples are noise here: trailing P/E is negative, and trailing return on equity is around -22%. The market will not price this stock off its recent history, and it is right not to.

The recovery since then is real and increasingly documented. In 2026 PRA earned $0.73 a share in Q1 and $1.51 in Q2, well ahead of the roughly $1 that analysts had expected. Cash collections hit $559 million in Q2, up 4% from $536 million a year earlier. Estimated remaining collections — ERC, the company's own measure of what it expects to collect from portfolios it already owns — reached a record $8.9 billion, up 7% year over year. Management also raised European ERC by $349 million after more than six years of European cash collections running above forecast. The PRA 3.0 restructuring delivered $35 million in annualized savings, net leverage fell for a seventh straight quarter to 2.67x, and a new $150 million buyback authorization let PRA repurchase $10 million of its own stock last quarter while shares sit at roughly 0.7x book value.

Here is the asterisk. Most of that Q2 earnings pop came from the European remeasurement — an adjustment to what the company expects to collect in future years, not cash that arrived in the quarter. Shifts in expected recoveries flow straight into revenue, and of Q2's $364.7 million in portfolio revenue, $96.9 million was labeled "changes in expected recoveries." Meanwhile the operating engine slowed: cash collections growth decelerated from 11% in Q1 to 4% in Q2. A beat built on an estimate revision, layered on top of decelerating cash momentum, is exactly the kind of quarter a market is entitled to look at twice.

Now price the risk, because the discount to Encore is not arbitrary. At roughly 8x forward earnings, the stock already embeds about $2.45 of earnings power in the year ahead — the market is not ignoring the recovery; it is paying for its continuation. And the book-value discount reflects what sits in front of that book. As a rough lens, the whole enterprise (equity plus debt) is marked near $4.2 billion against $8.9 billion of remaining estimated collections — about 47 cents per dollar, before lenders take their share. A meaningful haircut to expected recoveries would move the thinly supported equity by multiples. On top of that, PRA's U.S. collection arm, Portfolio Recovery Associates, has drawn CFPB enforcement more than once, with orders running back to 2015 and a 2023 repeat-offender settlement; and the U.S. legal channel those orders govern is the growth engine — legal-collection spending rose $15 million in Q1 alone.

Factor by factor, the stack reads like an improving report card rather than a finished one. Valuation is cheap by the numbers: 0.66x book and a forward P/E near 8x against a rival at about 2x book. Momentum confirms: the price sits above both its 50-day and 200-day averages, and management is buying below book. Revisions are moving the right way after three consecutive beats. But profitability on a trailing basis is still thin, and balance-sheet safety is the constraint rather than the tailwind — the factor that caps how much of the discount the market should close. AInvest's aggregate signal sits at Hold, and the data largely agrees.

What would change the case: cash collections re-accelerating on their own, without another remeasurement flattering the quarter, and the U.S. legal channel staying productive under the current compliance rules. Until then, a levered recovery priced at about 8x forward earnings is a name for a measured position, sized so that a haircut to expected recoveries cannot do the portfolio's job. The discount to book is the market charging interest on real risk, and the recovery has already been partly paid for in advance. The roughly 90% climb off the low was the easy leg; what is left is proof that collections follow through, and that arrives one quarterly report at a time.